Advanced age-related macular degeneration (AMD) is the leading cause of blindness in the
elderly, with limited therapeutic options. Here we report on a study of >12 million variants, …

We present a novel framework combining convolutional neural networks (CNN) and graph
search methods (termed as CNN-GS) for the automatic segmentation of nine layer …

Purpose To establish a process to evaluate and standardize a state-of-the-art nomenclature
for reporting neovascular age-related macular degeneration (AMD) data. Design …

<p>Retinal visual prostheses (“bionic eyes”) have the potential to restore vision to blind or
profoundly vision-impaired patients. The medical bionic technology used to design, …

Background Faricimab is a bispecific antibody that acts through dual inhibition of both
angiopoietin-2 and vascular endothelial growth factor A. We report primary results of two phase 3 …

Purpose To develop consensus terminology and criteria for defining atrophy based on OCT
findings in the setting of age-related macular degeneration (AMD). Design Consensus …

Malattia Leventinese (ML) and Doyne honeycomb retinal dystrophy (DHRD) refer to two
autosomal dominant diseases characterized by yellow-white deposits known as drusen that …

Objective To evaluate the safety and efficacy of individualized ranibizumab treatment in
patients with neovascular age-related macular degeneration. Design Twelve-month, phase III, …

OBJECTIVE:: To demonstrate noninferiority of a quarterly treatment regimen to a monthly
regimen of ranibizumab in patients with subfoveal choroidal neovascularization (CNV) …

Age-related macular degeneration (AMD) is the leading cause of legal blindness in the
industrialized world. AMD is characterized by accumulation of extracellular deposits, namely …